Internal Medicine, Gastroenterology · Boston, MA
NPI
1992729453
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
725 Albany St, Fl 6, Shapiro Bldg - Gastroenterology
Boston, MA, 02118
Phone (617) 414-6525
Groups this clinician bills Medicare through
Medicare paid, 2024
$18K
183 services
Medicare patients, 2024
122
Average age 69
Drug cost, 2024
$3.1M
310 prescriptions
Company payments, 2025
$0
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sharmeel K Wasan was code 99214 (office e&m - established), 32 times for 26 patients. In total Sharmeel K Wasan billed 183 services in 25 codes, and Medicare paid $18K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-06-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 32 | 26 | $71.14 | $2,277 |
| 99222 Hospital E&M - Initial | Facility | 24 | 23 | $108.87 | $2,613 |
| 45385 Colonoscopy - Lesion Removal | Facility | 20 | 20 | $214.16 | $4,283 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 17 | 13 | $13.82 | $235 |
| 43239 Upper GI Endoscopy | Facility | 12 | 12 | $83.60 | $1,003 |
By year: 2022 $16K for 156 services; 2023 $16K for 161 services; 2024 $18K for 183 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sharmeel K Wasan prescribed most often to Medicare patients was Stelara (Ustekinumab), with 75 prescriptions and refills. In total Sharmeel K Wasan wrote 310 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Stelara Ustekinumab | 75 | 95 | Under 11 | $2.0M |
| Rinvoq Upadacitinib | 34 | 34 | Under 11 | $244K |
| Skyrizi On-Body Risankizumab-Rzaa | 23 | 42 | Under 11 | $439K |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | 21 | 21 | 20 | $455 |
| Mesalamine Generic | 20 | 40 | Under 11 | $18K |
| Entyvio Pen Vedolizumab | 20 | 20 | Under 11 | $147K |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 14 | 14 | 13 | $255 |
| Lialda Mesalamine | 14 | 16 | Under 11 | $15K |
| Methotrexate Methotrexate Sodium | 11 | 12 | Under 11 | $239 |
| Omeprazole Generic | 11 | 21 | Under 11 | $138 |
Brand drugs: 221 claims; generic drugs: 89 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sharmeel K Wasan $0 (- in general payments such as food, travel and fees) from 2 companies.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.